PE72599A1 - SELECTIVE CARPROPHEN FOR COX-2, FOR THE TREATMENT OF PAIN AND INFLAMMATION IN DOGS - Google Patents

SELECTIVE CARPROPHEN FOR COX-2, FOR THE TREATMENT OF PAIN AND INFLAMMATION IN DOGS

Info

Publication number
PE72599A1
PE72599A1 PE1998000335A PE00033598A PE72599A1 PE 72599 A1 PE72599 A1 PE 72599A1 PE 1998000335 A PE1998000335 A PE 1998000335A PE 00033598 A PE00033598 A PE 00033598A PE 72599 A1 PE72599 A1 PE 72599A1
Authority
PE
Peru
Prior art keywords
cox
alkyl
carprophen
phenyl
dogs
Prior art date
Application number
PE1998000335A
Other languages
Spanish (es)
Inventor
Lundy Kristin Marie Marie
Anthony Paul Ricketts
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE72599A1 publication Critical patent/PE72599A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION PARA EL TRATAMIENTO O PREVENCION DEL DOLOR, PROCESOS Y ENFERMEDADES INFLAMATORIAS EN PERROS, ASOCIADOS CON LA ACTIVIDAD DE LA CICLOOXIGENASA-2 (COX-2) REDUCIENDO O ELIMINANDO LOS EFECTOS INDESEABLES ASOCIADOS CON LA INHIBICION DE LA ACTIVIDAD DE LA CICLOOXIGENASA-1 (COX-1); LA RELACION DE SELECTIVIDAD DE COX 2:COX 1 ES DE 3:1; EL INHIBIDOR ES UN COMPUESTO, DE FORMULA I, DONDE: R2 ES UN COMPUESTO DE FORMULA (a), A ES HIDROXI, ALCOXI C1-C4, AMINO, ENTRE OTROS; R6 ES HALOGENO, ALQUILO C1-C3, TRIFLUOROMETILO O NITRO; R9 ES H, ALQUILO C1-C2, FENILO O FENIL-ALQUILO C1-C2, FENILO OPCIONALMENTE SUSTITUIDO CON F, Cl, -C(=O)R; R ES ALQUILO C1-C2 O FENILO; "X" E "Y" SON H, ALQUILO C1-C2 Y DEFINEN ENANTIOMEROS (-)(R) Y (+)(S), DE PREFERENCIA CARPROFENO ACIDO-6-CLORO-ALFA-METIL-9H-CARBAZOL-2-ACETICO, SUS SALES. EL INHIBIDOR CARPROFENO SE PUEDE USAR JUNTO CON UNO O MAS AGENTES TERAPEUTICAMENTE ACTIVOS COMO ANTIBIOTICOS, ANTIFUNGICOS, ANTIPROTOZOOS, ANTIVIRALES Y OTROS INHIBIDORES DE LA INFLAMACIONREFERS TO A COMPOSITION FOR THE TREATMENT OR PREVENTION OF PAIN, PROCESSES AND INFLAMMATORY DISEASES IN DOGS, ASSOCIATED WITH THE ACTIVITY OF CYCLOOXYGENASE-2 (COX-2) REDUCING OR ELIMINATING THE INITIABLE EFFECTS ASSOCIATED WITH INATIO INATIO -1 (COX-1); THE COX 2: COX 1 SELECTIVITY RATIO IS 3: 1; THE INHIBITOR IS A COMPOUND, OF FORMULA I, WHERE: R2 IS A COMPOUND OF FORMULA (a), A IS HYDROXY, ALCOXI C1-C4, AMINO, AMONG OTHERS; R6 IS HALOGEN, C1-C3 ALKYL, TRIFLUOROMETILE OR NITRO; R9 IS H, C1-C2 ALKYL, PHENYL OR PHENYL-C1-C2-ALKYL, PHENYL OPTIONALLY SUBSTITUTED FOR F, Cl, -C (= O) R; R IS C1-C2 ALKYL OR PHENYL; "X" E "Y" ARE H, ALKYL C1-C2 AND DEFINE ENANTIOMERS (-) (R) Y (+) (S), OF PREFERENCE CARPROPHEN ACID-6-CHLORINE-ALPHA-METHYL-9H-CARBAZOL-2- ACETICO, ITS SALTS. THE CARPROPHEN INHIBITOR CAN BE USED TOGETHER WITH ONE OR MORE THERAPEUTICALLY ACTIVE AGENTS AS ANTIBIOTICS, ANTIFUNGALS, ANTIPROTOZOES, ANTIVIRALS AND OTHER INFLAMMATION INHIBITORS

PE1998000335A 1997-05-05 1998-05-04 SELECTIVE CARPROPHEN FOR COX-2, FOR THE TREATMENT OF PAIN AND INFLAMMATION IN DOGS PE72599A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4563597P 1997-05-05 1997-05-05

Publications (1)

Publication Number Publication Date
PE72599A1 true PE72599A1 (en) 1999-08-12

Family

ID=21939053

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000335A PE72599A1 (en) 1997-05-05 1998-05-04 SELECTIVE CARPROPHEN FOR COX-2, FOR THE TREATMENT OF PAIN AND INFLAMMATION IN DOGS

Country Status (32)

Country Link
EP (1) EP0988034A1 (en)
JP (1) JP2000513020A (en)
KR (2) KR20010012300A (en)
CN (1) CN1255059A (en)
AP (1) AP9801234A0 (en)
AR (2) AR011726A1 (en)
AU (1) AU6932198A (en)
BG (1) BG103852A (en)
BR (1) BR9808720A (en)
CA (1) CA2288759A1 (en)
DZ (1) DZ2479A1 (en)
EA (1) EA003696B1 (en)
GT (1) GT199800063A (en)
HR (1) HRP980244A2 (en)
HU (1) HUP0001286A3 (en)
ID (1) ID21311A (en)
IL (1) IL132570A0 (en)
IS (1) IS5220A (en)
MA (1) MA26491A1 (en)
NO (1) NO995389L (en)
NZ (1) NZ500183A (en)
OA (1) OA11213A (en)
PA (1) PA8450601A1 (en)
PE (1) PE72599A1 (en)
PL (1) PL337003A1 (en)
SK (1) SK148199A3 (en)
TN (1) TNSN98059A1 (en)
TW (1) TW590773B (en)
UY (1) UY24989A1 (en)
WO (1) WO1998050033A1 (en)
YU (1) YU55899A (en)
ZA (1) ZA983722B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245797B1 (en) 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
AU2003204888B2 (en) * 1998-05-22 2005-07-28 Pfizer Products Inc. Treating or Preventing the Early Stages of Degeneration of Articular Cartilage or Subchondral Bone in Mammals Using Carprofen and Derivatives
US6506785B2 (en) * 1998-05-22 2003-01-14 Pfizer, Inc. Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives
CA2347365A1 (en) * 1998-10-23 2000-05-04 Merck Frosst Canada & Co. Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use
DE60023119T2 (en) * 1999-03-10 2006-07-20 G.D. Searle Llc COMPOSITIONS FOR THE ADMINISTRATION OF A CYCLOOXYGENASE-2 HEMMER TO ANIMALS
WO2001034204A1 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001087343A2 (en) * 2000-05-15 2001-11-22 Merck Frosst Canada & Co. Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
PL206268B1 (en) 2000-06-13 2010-07-30 Wyethwyeth Analgesic and anti-inflammatory compositions containing cox-2 inhibitors
DE10032132A1 (en) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermal therapeutic system containing non-steroidal anti-inflammatory drugs with selective COX-2 inhibition
EP1307585B1 (en) 2000-08-07 2009-01-21 Vanderbilt University Compositions and methods for detecting and quantifying cox-2 activity and 2-arachidonylglycerol metabolites
WO2003007875A2 (en) * 2001-07-16 2003-01-30 Hoegestaett Edward Compounds with analgesic, antipyretic and/or anti-inflammatory activity
ES2275218T3 (en) 2003-05-07 2007-06-01 Osteologix A/S HYDROSOLUBLE STRONTIUM SALTS FOR THE TREATMENT OF CARTILAGOS AND / OR BONE AFFECTIONS.
MXPA06001288A (en) * 2003-07-31 2006-04-11 Upjohn Co Dispersible formulation of an anti-inflammatory agent.
EA200702280A1 (en) * 2005-05-20 2008-04-28 Пфайзер Лимитед SYNERGISTIC COMBINATIONS
JP2010523554A (en) 2007-04-04 2010-07-15 シグモイド・ファーマ・リミテッド Pharmaceutical composition of tacrolimus
US8951570B2 (en) 2007-04-26 2015-02-10 Sigmoid Pharma Limited Manufacture of multiple minicapsules
GB2483815B (en) 2009-05-18 2013-12-25 Sigmoid Pharma Ltd Composition comprising oil drops
CN107582526A (en) 2009-08-12 2018-01-16 希格默伊德药业有限公司 Immune regulation composite comprising polymer substrate and oil phase
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CN105939713A (en) 2014-03-06 2016-09-14 阿莱塔纳治疗学股份有限公司 Compositions of grapiprant and methods for using same
AU2015341695B2 (en) 2014-11-07 2021-07-08 Sublimity Therapeutics Limited Compositions comprising cyclosporin
WO2016112312A1 (en) * 2015-01-09 2016-07-14 Jaguar Animal Health Methods of treating diarrhea in companion animals
WO2021195346A1 (en) * 2020-03-25 2021-09-30 Sri International Lipoxygenase inhibitors
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
KR102404883B1 (en) 2020-11-30 2022-06-07 (주)이노보테라퓨틱스 Pharmaceutical composition for preventing or treating keloid or hypertrophic scar comprising Benzbromarone

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896145A (en) * 1972-07-24 1975-07-22 Hoffmann La Roche Carbazoles
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions

Also Published As

Publication number Publication date
HUP0001286A2 (en) 2000-11-28
GT199800063A (en) 1999-10-26
CA2288759A1 (en) 1998-11-12
WO1998050033A1 (en) 1998-11-12
PL337003A1 (en) 2000-07-31
EA199900895A1 (en) 2000-06-26
NZ500183A (en) 2002-04-26
ZA983722B (en) 1999-11-04
KR20010012300A (en) 2001-02-15
DZ2479A1 (en) 2003-02-01
AR011726A1 (en) 2000-08-30
AP9801234A0 (en) 1999-11-04
PA8450601A1 (en) 2000-05-24
MA26491A1 (en) 2004-12-20
NO995389D0 (en) 1999-11-04
EA003696B1 (en) 2003-08-28
OA11213A (en) 2003-07-14
SK148199A3 (en) 2001-09-11
IS5220A (en) 1999-10-19
AR039628A2 (en) 2005-03-02
YU55899A (en) 2003-08-29
KR20040004406A (en) 2004-01-13
UY24989A1 (en) 2001-10-25
AU6932198A (en) 1998-11-27
HUP0001286A3 (en) 2000-12-28
CN1255059A (en) 2000-05-31
TW590773B (en) 2004-06-11
EP0988034A1 (en) 2000-03-29
NO995389L (en) 2000-01-04
ID21311A (en) 1999-05-20
HRP980244A2 (en) 1999-02-28
JP2000513020A (en) 2000-10-03
BG103852A (en) 2000-06-30
BR9808720A (en) 2000-07-11
IL132570A0 (en) 2001-03-19
TNSN98059A1 (en) 2005-03-15

Similar Documents

Publication Publication Date Title
PE72599A1 (en) SELECTIVE CARPROPHEN FOR COX-2, FOR THE TREATMENT OF PAIN AND INFLAMMATION IN DOGS
ES2170252T3 (en) TETRAHYDROIMIDAZOPIRIDOINDOLDIONAS AS INHIBITORS OF SPECIFIC CGMP PDE.
NI200300042A (en) COMPOUNDS THAT MODULATE THE ACTIVITY OF PPAR AND METHODS FOR ITS PREPARATION.
AR027518A1 (en) SUNFLOWER INHIBITORS AND USES OF THE SAME
CR7865A (en) DERIVATIVES OF DIHYDROPIRANOINDOL -3,4-DIONA SUBSTITUTED AND DERIVATIVES OF 2-HYDROXIMETHYLINDOL OF THE 3-OXOACETIC ACID REPLACED AS INHIBITORS OF THE PLASMINOGEN 1 ACTIVATOR INHIBITOR (PAI-1)
PE20091065A1 (en) BIS- (SULFONYLAMINE) DERIVATIVES IN THERAPY 066
PE20040411A1 (en) ARYL KETONE PIRROLO TRIAZINE COMPOUNDS
NI200500087A (en) DERIVATIVES 4-TETRAZOLYL-4 PHENYLPIPERIDINE FOR PAIN TREATMENT
ES2192588T3 (en) 4- (ARILAMINOMETILEN) -2,4-DIHIDRO-PIRAZOL-3-ONAS.
PA8501801A1 (en) TRIMYCLY POLYMERASE INHIBITORS (ADP - POLIRRIBOSAS)
ES2177112T3 (en) ANGIOSTATIC AGENTS AND COMPOSITIONS TO TREAT GLAUCOMA GLC1A.
ES2183937T3 (en) INHIBITORS OF THE CELL ADHESION.
AR035417A1 (en) TRICYCLE DERIVATIVES OF LACTAMA AND SULTAMA, PROCESSES FOR THEIR DEVELOPMENT, DRUGS THAT CONTAIN THEM, AND THE USE OF SUCH COMPOUNDS IN THE PREPARATION OF DRUGS
ES2421948T3 (en) Compounds and compositions for delivering active agents
TR200200263T2 (en) New selective retinoid agonists
ES2164924T3 (en) CEPHALOSPORINE ANTIBIOTICS.
AR052885A1 (en) QT INTERVAL CONTROL METHODS
ES543282A0 (en) PROCEDURE TO PREPARE NEW SUBSTITUTED BIS- (4-AMINOPHENYL) -SULFO-NAS
UY26847A1 (en) PIRROLIDINE DERIVATIVES
SE9702563D0 (en) Compounds
PE20230679A1 (en) HETEROCYCLIC PAD4 INHIBITORS
UY26895A1 (en) PIRAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS TO MODULATE AND / OR INHIBIT THE ACTIVITY OF ERAB / HADH2
AR025379A1 (en) 9A-AZALIDAS WITH ANTIBACTERIAL ACTIVITY.
PA8522301A1 (en) PIRROLIDINE DERIVATIVES
PE20040906A1 (en) MORPHOLINE DERIVATIVES AS DOPAMINE AGONISTS

Legal Events

Date Code Title Description
FC Refusal